Patent reform bill stalls on differing needs

03/24/2008 | San Diego Business Journal

The Patent Reform Act of 2007 has stalled in a Senate committee as stakeholders in high-tech companies and the drug industry talk with senators about the different consequences of the bill for their work. "The high-tech guys and biotech guys have divergent interests, which is problematic. There's huge lobbying on both sides and they're not in agreement," the president and CEO of Novalar Pharmaceuticals said.

View Full Article in:

San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ